NCT04799002招募中3 期
Choice of Topotecan or Melphalan in Retinoblastoma Patients
Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2021年3月11日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Eyeball-sparing rate
研究概览
简要总结
The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.
详细描述
To evaluate the effectiveness and complications of topotecan and melphalan for intraocular injection in retinoblastoma patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •diagnosed as retinoblastoma
- •receiving eyeball-sparing treatment
排除标准
- •disease progression during follow-up
研究组 & 干预措施
Topotecan
Active Comparator
Topotecan intraocular injection during chemotherapy
干预措施: Topotecan (Drug)
Melphalan
Experimental
Melphalan intraocular injection during chemotherapy
干预措施: Melphalan (Drug)
结局指标
主要结局
Eyeball-sparing rate
时间窗: 5 years after chemotherapy
Eyeball-sparing rate during chemotherapy in retinoblastoma patients
次要结局
- Side effects(5 years after chemotherapy)
研究者
Huasheng Yang
Principal Investigator
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb TrialEpithelial Ovarian CancerNCT01630018Chong Kun Dang Pharmaceutical141
Unknown
1 期
Intra-arterial Chemotherapy for Children With RetinoblastomaRetinoblastomaNCT00906113Hadassah Medical Organization10
终止
早期 1 期
Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV GliomaGlioma of BrainNCT03927274H. Lee Moffitt Cancer Center and Research Institute3
已完成
1 期
Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.Multiple MyelomaNCT00325416H. Lee Moffitt Cancer Center and Research Institute177
终止
不适用
Intravitreal Injections of Melphalan for RetinoblastomaRetinoblastomaNCT01558960Hadassah Medical Organization10